Abstract

Development of Phenotypic High-Content Assays for Compound Screening and Hit Validation

Kamyar Hadian, Group Leader, Helmholtz Zentrum München

Phenotypic screening has highly emerged in the past decade. Especially High-Content Screening (HCS) has gained strong acceptance in the field of target validation, compound screening and compound profiling as a technology that allows pushing towards innovative and biologically relevant systems. Here the imaging devices and the analysis software have evolved tremendously providing a versatile tool for chemical biology and drug discovery purposes. We have established the necessary infrastructure to run HCS projects in different target areas with various given complexities either in primary larger screening campaigns or in the course of hit validation/profiling in cells. In the past years, we have focused on applying stem cell- and 3D-based high-content assays for compound screening activities, but also developed strategies to multiplex HCS and HTS. This lecture will give insight into some projects that have accomplished in recent years.